Follow The Filings

IONS Ionis Pharmaceuticals Inc.

Health Care, filed as IONIS PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q2

  • 4 Owners
  • Max 13.7%
  • $207M
  • 1 reduce 1 exit 3 small

In 2026 Q2 Ron Baron trimmed Ionis Pharmaceuticals, and Farallon Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 13.7% (Tweedy, Browne Co.). Not free-float ownership.

  1. Tweedy, Browne Co. Add 13.7%
  2. Cathie Wood Add 0.15%
  3. Murray Stahl Reduce 0.01%

Who owns IONS

Sorted by value, long equity only, as of 2026 Q2.

History
Tweedy, Browne Co. 13.7%, was 13.6% Small add +0.2% 2,280,311 $181M History
Cathie Wood, Ark Investment Management 0.15% Small add +4.2% 300,770 $24M History
Ron Baron, Bamco Inc. (Baron Capital) <0.01%, was 0.01% Reduce −68.9% 14,000 $1.1M History
Murray Stahl, Horizon Kinetics Asset Management 0.01% Small trim −4.6% 10,904 $865K History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 4,800 $360K History

4 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by IONS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IONS insider trades
  • $1.1M bought by 1 insider
  • $11.9M sold by 9 insiders outside a trading plan
  • $102M sold by 18 insiders under 10b5-1 plans
  1. Michael R Hayden Director
    Buy
    $1.1M 20,000 shares at $52.94 +500% to stake
    Traded Jul 30–31 Filed Jul 31
    ↗
  2. C Frank Bennett EVP, Chief Scientific Officer
    Planned sale
    $1.7M 20,536 shares at $84.95
    Traded Jul 7 Filed Jul 9
    ↗
  3. Allene M. Diaz Director
    Planned sale
    $864K 10,111 shares at $85.42 73% of stake
    Traded Jul 7 Filed Jul 9
    ↗
  4. Holly B. Kordasiewicz EVP, Chief Development Officer
    Planned sale
    $31K 362 shares at $84.30 1.6% of stake
    Traded Jul 7 Filed Jul 9
    ↗
  5. Joseph Klein III Director
    Planned sale
    $910K 11,518 shares at $79.04 51% of stake
    Traded Jul 1 Filed Jul 6
    ↗
  6. Joseph Baroldi EVP, Chief Business Officer
    Planned sale
    $452K 5,635 shares at $80.16 55% of stake
    Traded Jun 26 Filed Jun 30
    ↗
  7. Patrick R. O'Neil EVP CLO & General Counsel
    Planned sale
    $246K 3,069 shares at $80.00 4.8% of stake
    Traded Jun 26 Filed Jun 30
    ↗
  8. Eugene Schneider EVP, Chf Clinical Develop Ofcr
    Planned sale
    $2.1M 26,000 shares at $81.05 25% of stake
    Traded Jun 26 Filed Jun 30
    ↗
  9. Brett P Monia CEO
    Planned sale
    $6.8M 85,637 shares at $79.70 26% of stake
    Traded Jun 24–26 Filed Jun 26
    ↗
  10. Eric Swayze EVP Research
    Planned sale
    $839K 10,602 shares at $79.18 33% of stake
    Traded Jun 25 Filed Jun 26
    ↗
  11. Holly B. Kordasiewicz EVP, Chief Development Officer
    Planned sale
    $4.5M 60,846 shares at $73.41 73% of stake
    Traded Jun 12 Filed Jun 16
    ↗
  12. Spencer R Berthelsen Director
    Planned sale
    $588K 8,000 shares at $73.49 4.9% of stake
    Traded Jun 15 Filed Jun 16
    ↗
  13. Spencer R Berthelsen Director
    Planned sale
    $605K 8,000 shares at $75.67 4.9% of stake
    Traded Jun 1 Filed Jun 3
    ↗
  14. Brett P Monia CEO
    Planned sale
    $356K 4,536 shares at $78.49 1.8% of stake
    Traded May 13–14 Filed May 15
    ↗
  15. Joseph Loscalzo Director
    Planned sale
    $5.8M 77,289 shares at $75.06 68% of stake
    Traded May 4 Filed May 6
    ↗

Also filed in the last 12 months, not counted as buying or selling: 95 option exercises, 18 sales to cover taxes, 11 other transactions, and 8 stock grants.

SEC filings

Recent issuer filings from EDGAR, 11 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q IONIS PHARMACEUTICALS, INC. 10-Q 06-30-2026 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 9 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $787.65M $705.14M $943.71M
Gross profit * $778.51M $693.92M $927.8M
Gross margin * 98.8% 98.4% 98.3%
Net income -$366.29M -$453.9M -$381.39M
Net margin * -46.5% -64.4% -40.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $2.64B $2.62B $2.99B
Total non-current assets * $348.22M $383.38M $533.2M
Total assets $2.99B $3B $3.52B
Total current liabilities $448.09M $309.32M $781.57M
Total non-current liabilities * $2.16B $2.11B $2.25B
Total equity $386.69M $588.35M $489.09M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$307.51M -$500.95M -$268.58M
Cash from investing -$214.13M -$134.03M -$277.78M
Cash from financing $644.08M $478.06M $675.84M
Net change in cash $122.79M -$157.19M $130.18M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf